Search clinical trials for: LAF237 (vildagliptin)

Total 192 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis

Completed

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Prediabetic State

United States
Novartis

Completed

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Type 2 Diabetes Mellitus

Germany
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

Diabetes Mellitus
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Korea University Anam Hospital

Unknown

Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

Diabetes Mellitus | Oxidative Stress

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Rio de Janeiro State University
Laboratory for Clinical and Experimental Research on Vascular Biology

Completed

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

1- Microvascular Function | 2-oxidative Stress | 3-inflammation

Brazil
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

Diabetes Mellitus, Type 2

United States, Hungary, Poland, Germany, France
Pusan National University Hospital

Completed

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of
Universitaire Ziekenhuizen KU Leuven

Completed

Vildagliptin on Gastric Accommodation

Healthy
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
University Hospital, Strasbourg, France
Novartis

Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Haemodialyzed, Type 2 Diabetes

France
Institut fur Diabetesforschung, Munich, Germany

Unknown

PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)

Insulin-dependent Gestational Diabetes

Germany
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis

Completed

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Diabetes Mellitus, Type 2

Switzerland
Chiang Mai University

Completed

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Diabetes Mellitus, Type 2 | Ischemic Heart Disease

Thailand
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine
Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
PegBio Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

China, Taiwan, Hong Kong
Sanofi

Completed

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Russian Federation
University of Catania

Completed

Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment

Mild Cognitive Impairment
MTI University

Completed

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients

Egypt
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Sadat City University

Recruiting

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Schizophrenia | Dyslipidemias

Egypt
Triangle Pharmaceuticals

Completed

A Study of MKC-442 in HIV-Positive Patients

HIV Infections
Sherief Abd-Elsalam

Recruiting

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

dm

Egypt
Clinision

Withdrawn

Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy. (GRIP)

Diabetes Mellitus, Type 2
Reseach Laboratory of Clinical and Experimental...
La Société Arabe des Industries Pharmaceutiques-Tunisie; Centre National Chalbi...

Completed

Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®

Fed Conditions

Tunisia
AET Laboratories Private Limited

Completed

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

To Determine Bioequivalence Under Fed Conditions
Novartis Pharmaceuticals

Completed

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Type 2 Diabetes Mellitus

Egypt, United Kingdom, Turkey, Lebanon, Russian Federation, Tunisia, Malaysia, Germany, Spain, Saudi Arabia, Denmark, Indonesia, Jordan, Kuwait, Singapore, United Arab Emirates
The First Affiliated Hospital of Xiamen University

Unknown

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

T2DM

China
Sheba Medical Center

Completed

Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease (VAAST)

Type 2 Diabetes Mellitus | Ischemic Heart Disease

Israel
October 6 University

Recruiting

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Poly Cystic Ovary Syndrome

Egypt
Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

To Determine Bioequivalence Under Fed Conditions
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Diabetes Mellitus, Type 2

United States
Hospital de Clinicas de Porto Alegre

Unknown

Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes (DIABEX-VILDA)

Diabetes Mellitus, Type 2 | Exercise | Hypoglycemic Agents | Diabetic Blood Glucose Monitoring

Brazil
Novartis Pharmaceuticals

Completed

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications (PREFER)

Type 2 Diabetes

Germany
Samsung Medical Center
Novartis

Completed

The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Yaounde Central Hospital
University of Yaounde 1; University of Buea

Completed

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes (LIRAVIS)

Type 2 Diabetes Mellitus

Cameroon
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States

3

Subscribe